Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out what effects of using adaptive radiotherapy to deliver chest radiation has on the ability to control lung cancer and side effects.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AHS Cancer Control Alberta

Criteria

Inclusion Criteria:

• Minimum 18 years of age

• Biopsy proven, newly diagnosed, untreated SCLC

• Completed standard of care staging investigations including: CT chest/abdomen/pelvis, bone scan or PET scan, CT head or MRI brain, or chest X-ray

• Eligible for platinum doublet chemotherapy

• Eligible for thoracic radiotherapy, which can also include ipsilateral

• Capable of providing written, informed consent prior to participation

• Able and willing to comply with protocol rules and follow-up regimen

• Performance status of ECOG 0-2

• Pulmonary function tests showing FEV-1 >1.0L and DLCO > 50% predicted

• Radiation-targetable intrathoracic disease supraclavicular lymph node disease

Exclusion Criteria:

• No intrathoracic disease seen to target with radiation

• Thoracic disease is contiguous to extra-thoracic sites, beyond ipsilateral supraclavicular lymph nodes

• Mixed histology disease

• Active serious infection requiring therapy

• Brain metastasis that has not been symptomatically stable on dexamethasone

• 4 or more sites of extrathoracic disease, even if 2 or more of these are present in the same organ system

• Previous CNS or thoracic radiotherapy

• Previous chemotherapy

• Ineligibility for platinum doublet chemotherapy

• Life expectancy of less than 3 months

• Prior thoracic surgery

• History of carcinoma other than cutaneous basal cell carcinoma

• Pregnant or breast-feeding

• In LS-SCLC, patients that are not eligible for concurrent chemoradiotherapy

• In ES-SCLC, patients that are not eligible for concurrent chemoradiotherapy under the experimental arm

• CT contrast allergy or kidney disease with irreversibly low creatinine clearance inadequate for IV contrast administration (for the purposes of high quality contrast enhanced CT chest and abdomen for follow-up imaging)